Presented by The American Association of Immunologists (AAI) in collaboration with the Society for Immunotherapy of Cancer
The Annual Meeting of AAI on May 12-16, 2017, will present expert and recent research findings in immunology through lectures, major symposia, and oral and poster sessions. SITC was again selected as a guest society, to present a two-hour symposium at AAI's Immunology 2017TM.
The topic of the SITC symposium this year is Mechanisms of Resistance to Immunotherapy. Studies performed in the past decade have shown that PD-1/PD-L1 antagonists are among the most effective therapies for treatment of advanced cancer. Despite these advances, the following topics remain poorly understood—the mechanisms by which PD-1 engagement suppresses immune cell function; the immune responses which produce anti-tumor effects following therapy with anti-PD-1 or anti-PD-L1; and other critical pathways which permit tumor evasion from immune responses. Basic and translational immunologists are expanding the current understanding of tumor immunobiology, and insights from these investigations should lead to novel immune modulatory strategies, rational combination approaches, and most importantly, predictive biomarkers to select the best immune modulatory strategy for each individual patient. The symposium will highlight selected, recent translational efforts investigating human tumor immunobiology in patients with metastatic cancer before and after immune modulation.
Learn more about this meeting and register to attend here!
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center
Mario Sznol, MD – Yale School of Medicine
Session Speakers and Topics
#Oncologist #Researcher #2017 #Collaboration
|8 – 8:20 a.m.
||Characterizing Tumor-Specific T-Cell responses in Tumors With Low Mutation Rates
Steven A. Rosenberg, MD, PhD – National Cancer Institute
|8:20 – 8:40 a.m.
||Pathway and Mutation Analyses in Melanoma Tumors Resistant to Anti-PD-1
Roger S. Lo, MD, PhD – University of California, Los Angeles
|8:40 – 9 a.m.
||Insights Into Mechanisms of Immune Cell Antagonism by PD-1 Engagement in Animal Models
Ira Mellman, PhD – Genentech
|9 – 9:20 a.m.
||Use of shRNA Screens to Identify Novel Immune Checkpoints
Louis M. Weiner, MD – Georgetown Lombardi Comprehensive Cancer Center
|9:20 – 9:40 a.m.
||Role of Receptor Tyrosine Kinases in Function of Intratumoral Monocytes and Macrophages
Carla V. Rothlin, PhD – Yale University
|9:40 – 10 a.m.
||Role of Oxygen in Immunosuppression
Nicholas P. Restifo, MD – National Cancer Institute